BIOTRONIK Blog

BIOTRONIK, a global leader in cardiovascular, endovascular, and neuromodulation solutions, today announces the launch of BIOMAG-LL, a pre-market trial focused on confirming the safety and clinical performance of Freesolve ® Resorbable Magnesium Scaffold (RMS), for the treatment of long de novo lesions in native coronary arteries. The BIOMAG-LL is a prospective, international, multi-center, single arm pre-market study that will enroll 100 patients in Europe with de novo coronary artery stenosis and long lesions. Given that the Freesolve RMS is already CE-certified for shorter lesions, the

BIOTRONIK Neuro will unveil new data from the BENEFIT-03 clinical study at the North American Neuromodulation Society (NANS) 2025 Annual Meeting. The findings highlight the transformative potential of its Prospera TM Spinal Cord Stimulation (SCS) system. This system integrates RESONANCE™ multiphase stimulation with automatic, objective, daily remote monitoring and proactive care* to optimize management of SCS patients’ chronic pain. 1 The 24-month data revealed that participants experienced significant pain relief, along with better sleep, improved function and reduced opioid medication use

BIOTRONIK, a global leader in cardiovascular, endovascular, and neuromodulation solutions, is pleased to announce today the approval of two new indications for the Orsiro ® Mission Drug-Eluting Stent (DES): One-month Dual Antiplatelet Therapy (DAPT) for High Bleeding Risk (HBR) Patients: Allows practitioners to offer personalized, shorter DAPT durations to their patients at high risk of bleeding events, in accordance with the most recent guidelines. Calcified Lesions Treatment: Allows practitioners to target more complex lesions with moderate or severe calcification. These new indications